Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01898273 · ClinicalTrials.gov registry record · Phase 2
Imaging Trial With I-124-CLR1404 in Patients With Newly Diagnosed or Recurrent Glioblastoma
A Phase 2 study, sponsored by Cellectar Biosciences.
- Terminated
- Registry status
- Phase 2
- Development phase
- 7
- Enrollment target
NCT01898273: Clinical Trial Phase 2 study, sponsored by Cellectar Biosciences.
NCT01898273 is a Phase 2 study that was terminated before completion, run by Cellectar Biosciences. The registered enrollment target is 7 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (95% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01898273, a Phase 2 study, was terminated before completion, sponsored by Cellectar Biosciences.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 7 participants
- Enrollment target
Study Summary
The primary objective of this trial is to determine the optimal dose and imaging time point(s) of I-124-CLR1404 in subjects with newly diagnosed and recurrent glioma to be used in future trials.
Primary Outcome
Up to two dose levels (5 mCi and 7.5 mCi) will be evaluated in conjunction with multiple imaging time points to determine the optimal parameters for PET/CT brain imaging. Dosing will begin at 5 mCi and if the images are deemed inadequate, as assessed by count statistics and image quality, the 7.5 mCi dose level will be evaluated.
Interventions
- DRUG I-124-CLR1404
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7 participants |
| Start Date | 2014-02 |
| Est. Completion | 2015-12 |
| Phase | Phase 2 |
Why NCT01898273 stopped before completion
NCT01898273 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 7 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (95% lower).
The record links to 0 conditions, and to 1 intervention - of which I-124-CLR1404 is the first listed.
NCT01898273 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01898273 about?
NCT01898273 is a clinical study titled "Imaging Trial With I-124-CLR1404 in Patients With Newly Diagnosed or Recurrent Glioblastoma". The primary objective of this trial is to determine the optimal dose and imaging time point(s) of I-124-CLR1404 in subjects with newly diagnosed and recurrent glioma to be used in future trials.
What is the current status of trial NCT01898273?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 7 participants. The study started on 2014-02. Estimated completion is 2015-12.
What interventions are being tested in trial NCT01898273?
The interventions under investigation include: I-124-CLR1404 (DRUG).
Who is sponsoring clinical trial NCT01898273?
This trial is sponsored by Cellectar Biosciences, which has 10 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01898273's enrollment target sits among peer trials
7 1996th of 2000 higher than 5 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia